In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

The increasing occurrence of chronic and infectious diseases is the main driver of the rising demand for interferon. Furthermore, advancements in interferon production and ongoing research and ...

The University of Copenhagen is excited to announce TruDiagnostic, a leader in epigenetic testing, will present its latest ...

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...

Operator Good afternoon, and welcome to AbCellera's full-year 2024 business update conference call. My name is Tamia, and I will facilitate the audio portion of today's interactive broadcast.

Biogen Option Activity Analysis: Last 30 Days Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and ...

Shares of NYSEARCA IDEV opened at $69.87 on Wednesday. iShares Core MSCI International Developed Markets ETF has a 52 week low of $62.39 and a 52 week high of $71.54.